Bio-path Holdings Stock News

HOUSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a p

Preliminary Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML Patients Preliminary Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML Patients

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

Analysts expect Bio-Path Holdings, Inc. (NASDAQ:BPTH) to post earnings of ($0.32) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Bio-Paths earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.35). Bio-Path posted earnings of ($0.57) per share during the same quarter last year, []

Bio-Path (NASDAQ:BPTH)s stock had its buy rating reaffirmed by analysts at HC Wainwright in a research report issued to clients and investors on Monday, Price Targets.com reports. They currently have a $12.00 price target on the stock. HC Wainwrights price target indicates a potential upside of 162.58% from the companys current price. Separately, Zacks Investment []

Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q3 2021 Results - Earnings Call Transcript

HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a p

BioPath (BPTH) stock is soaring higher on Tuesday after revealing an update from the FDA on its IND application for BP1002. The post BPTH Stock: The Good News That Has BioPath Investors Smiling Today

BPTH stock is shooting up this morning as the company reveals a new plan for evaluating the effectiveness of one of its drugs. The post BPTH Stock: Why Little-Known Bio-Path Holding Just Popped More T

Bio-Path Holdings Inc (NASDAQ: BPTH) is surging higher Tuesday after the company announced the U.S Food and Drug Administration reviewed and cleared its Investigational New Drug application for B

The FDA has signed off Bio-Path Holdings Inc's (NASDAQ: BPTH) Investigational New Drug (IND) application for BP1002 in refractory/relapsed acute myeloid leukemia (AML) patients. In Phase 1/ 1b tria

The shares of Bio-Path Holdings, Inc. (NASDAQ: BPTH) increased by over 30% pre-market. This is why it happened.

Phase 1/ 1b Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed AML Patients Phase 1/ 1b Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 P

Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q2 2021 Results - Earnings Call Transcript

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET